5-fluorouracil + octreotide

5-fluorouracil + octreotide is a combination of two pharmaceutical agents used primarily in the context of cancer therapy and its complications. 5-fluorouracil (5-FU) is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis and exerting cytotoxic effects on rapidly dividing tumor cells[4]. Octreotide is a synthetic somatostatin analogue that inhibits the secretion of various gastrointestinal hormones, reduces intestinal secretions, and slows gastrointestinal motility[2][5]. This combination has been investigated for use in managing severe chemotherapy-induced diarrhea (CID), particularly when caused by regimens containing 5-fluorouracil. Octreotide helps control refractory diarrhea associated with chemotherapy by reducing gut hormone secretion and increasing GI transit time[1][2]. Additionally, both drugs have been studied together for their potential to attenuate local inflammation (by 5-FU) and inhibit autodigestive processes (by octreotide) in conditions such as acute pancreatitis[3].

Other names

continuous 5-fluorouracil infusion plus long-acting octreotidecontinuous5-fluorouracil infusion plus long-acting octreotidecontinuous-5-fluorouracil infusion plus long-acting octreotidemetronomic 5-fluorouracil plus octreotidemetronomic5-fluorouracil plus octreotidemetronomic-5-fluorouracil plus octreotide5-FU + octreotide LAR